1. Market Research
  2. > Sezary Syndrome – Pipeline Review, H1 2013

Sezary Syndrome – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 29 pages

Sezary Syndrome – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sezary Syndrome.
- A review of the Sezary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sezary Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sezary Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sezary Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Sezary Syndrome - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Sezary Syndrome Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Sezary Syndrome 6
Sezary Syndrome Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Pre-Clinical Stage Products 11
Comparative Analysis 11
Sezary Syndrome Therapeutics - Products under Development by Companies 12
Companies Involved in Sezary Syndrome Therapeutics Development 13
Shionogi and Co., Ltd. 13
Innate Pharma SA 14
Spectrum Pharmaceuticals, Inc. 15
Sezary Syndrome - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
IPH-41 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
[pralatrexate] + [bexarotene] - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
interferon gamma-1a - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Sezary Syndrome Therapeutics - Drug Profile Updates 26
Sezary Syndrome Therapeutics - Dormant Products 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29



List of Tables

Number of Products Under Development for Sezary Syndrome, H1 2013 6
Products under Development for Sezary Syndrome - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Mid Clinical Stage Development, H1 2013 9
Comparative Analysis by Early Clinical Stage Development, H1 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Shionogi and Co., Ltd., H1 2013 13
Innate Pharma SA, H1 2013 14
Spectrum Pharmaceuticals, Inc., H1 2013 15
Assessment by Monotherapy Products, H1 2013 16
Assessment by Combination Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Sezary Syndrome Therapeutics - Drug Profile Updates 26
Sezary Syndrome Therapeutics - Dormant Products 27



List of Figures

Number of Products under Development for Sezary Syndrome, H1 2013 6
Products under Development for Sezary Syndrome - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Mid Clinical Stage Products, H1 2013 9
Early Clinical Stage Products, H1 2013 10
Pre-Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 16
Assessment by Combination Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.